A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 in Patients With CD20-Expressing Hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2017
At a glance
- Drugs XmAb 13676 (Primary)
- Indications B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Xencor
- 10 Aug 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Aug 2020.
- 09 May 2017 According to a Xencor media release, initial data is expected in 2018.
- 28 Feb 2017 According to a Xencor media release, first patient has been dosed.